Pub Date : 2025-03-01DOI: 10.1016/j.endien.2025.101535
Elena Carrillo-López, Maria Sara Tapia-Sanchiz, Sara Jiménez-Blanco, Begoña Molina-Baena
d-Lactic acidosis is an uncommon cause of acidosis that occurs in patients with short bowel syndrome (SBS). Reduced intestinal absorption surface leads to carbohydrate malabsorption, fermented by abnormal colonic bacterial flora, resulting in elevated d-lactate levels. It should be suspected in SBS patients who exhibit typical neurological symptoms without other apparent causes, along with metabolic acidosis with normal l-lactate levels. Treatment involves correcting acidosis and managing bacterial overgrowth with non-absorbable antibiotics.
This report presents a case of a patient on teduglutide for SBS who experienced an episode of d-lactic acidosis. To date, there are no documented cases in the literature of similar episodes in adult patients undergoing therapy with GLP2 analogs.
{"title":"Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide","authors":"Elena Carrillo-López, Maria Sara Tapia-Sanchiz, Sara Jiménez-Blanco, Begoña Molina-Baena","doi":"10.1016/j.endien.2025.101535","DOIUrl":"10.1016/j.endien.2025.101535","url":null,"abstract":"<div><div><span>d</span>-Lactic acidosis is an uncommon cause of acidosis that occurs in patients with short bowel syndrome (SBS). Reduced intestinal absorption surface leads to carbohydrate malabsorption, fermented by abnormal colonic bacterial flora, resulting in elevated <span>d</span>-lactate levels. It should be suspected in SBS patients who exhibit typical neurological symptoms without other apparent causes, along with metabolic acidosis with normal <span>l</span>-lactate levels. Treatment involves correcting acidosis and managing bacterial overgrowth with non-absorbable antibiotics.</div><div>This report presents a case of a patient on teduglutide for SBS who experienced an episode of <span>d</span>-lactic acidosis. To date, there are no documented cases in the literature of similar episodes in adult patients undergoing therapy with GLP2 analogs.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101535"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.endien.2025.101531
Juan José Díez , Emma Anda , Irene Bretón , Cintia González-Blanco , María Miguélez , Ana Zugasti , Alberto Fernández , on behalf of the Sociedad Española de Endocrinología y Nutrición
Quality healthcare should be grounded on clinical practice with the highest benefit-risk ratio and cost-effectiveness according to the available scientific evidence. The overuse of unproven diagnostic or therapeutic procedures is common in our setting and leads to increased healthcare spending and even iatrogenic harm. Previous cost-effectiveness initiatives have proposed identifying diagnostic and therapeutic measures that are better 'not done' in certain clinical contexts under the lens of the available scientific evidence. In this regard, the Spanish Society of Endocrinology and Nutrition (SEEN) has compiled a series of 'not-to-do' recommendations from its various working groups. These recommendations cover common clinical situations classified into the following thematic areas: diabetes, nutrition, pituitary gland, neuroendocrine tumors, thyroid, and hormone replacement therapy in postmenopausal women.
{"title":"Recommendations of the Spanish Society of Endocrinology and Nutrition (SEEN) on “what not to do” in clinical practice","authors":"Juan José Díez , Emma Anda , Irene Bretón , Cintia González-Blanco , María Miguélez , Ana Zugasti , Alberto Fernández , on behalf of the Sociedad Española de Endocrinología y Nutrición","doi":"10.1016/j.endien.2025.101531","DOIUrl":"10.1016/j.endien.2025.101531","url":null,"abstract":"<div><div>Quality healthcare should be grounded on clinical practice with the highest benefit-risk ratio and cost-effectiveness according to the available scientific evidence. The overuse of unproven diagnostic or therapeutic procedures is common in our setting and leads to increased healthcare spending and even iatrogenic harm. Previous cost-effectiveness initiatives have proposed identifying diagnostic and therapeutic measures that are better 'not done' in certain clinical contexts under the lens of the available scientific evidence. In this regard, the Spanish Society of Endocrinology and Nutrition (SEEN) has compiled a series of 'not-to-do' recommendations from its various working groups. These recommendations cover common clinical situations classified into the following thematic areas: diabetes, nutrition, pituitary gland, neuroendocrine tumors, thyroid, and hormone replacement therapy in postmenopausal women.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101531"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.endien.2025.101540
Antonio Bustos-Merlo, Carlos Javier García Calvente, Antonio Rosales-Castillo
{"title":"Addendum to “The importance of MLPA technique in the diagnosis of multiple endocrine neoplasia type”, Endocrinología, Diabetes y Nutrición 71 (2024) 221-225","authors":"Antonio Bustos-Merlo, Carlos Javier García Calvente, Antonio Rosales-Castillo","doi":"10.1016/j.endien.2025.101540","DOIUrl":"10.1016/j.endien.2025.101540","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101540"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.endien.2025.101530
Ricard Onieva Carbajo , Joan Carles Ferreres Piñas , Flavia Alberto , Ismael Capel Flores , Martina Pérez , Maria Rosa Bella Cueto
Introduction
The tall cell subtype of papillary thyroid carcinoma (PTC) is considered to have poor prognosis, but its diagnostic criteria have been modified on several occasions. The aim of our study was to find the best diagnostic criteria to relate the tall cell subtype with aggressiveness and poor prognosis.
Material and methods
In 171 cases of classic subtype and tall cell subtype of PTC, the percentage of cells between two and three times taller than wide (C2−3) and cells more than three times taller than wide (Cx3) was determined by two observers, after obtaining reference images. Groups were made based on the percentage of cells of each component (<2%, between 2 and 10%, between 11 and 30%, between 31 and 50% and >50%) and were correlated with clinical and histopathological data. Interobserver agreement was also assessed.
Results
According to the current WHO classification criteria, only 8 cases (5%) of tall cell subtype were identified. The comparison of the risk of recurrence at 5 years based on the percentage and type of cells showed that it increased significantly from >10% of the Cx3 cell component, while there were no significant differences in recurrence rate with any C2−3 cell percentages. Very good interobserver agreement was obtained (Kappa index: 0.83).
Conclusions
We consider relevant reporting the presence of Cx3 cells from 10% in PTC as it is associated with a significant increase in the recurrence rate at 5 years. Interobserver agreement is very good if reference images are available.
{"title":"Analysis of cell height in the tall cell subtype of papillary thyroid carcinoma. Is it a key factor in the prognosis?","authors":"Ricard Onieva Carbajo , Joan Carles Ferreres Piñas , Flavia Alberto , Ismael Capel Flores , Martina Pérez , Maria Rosa Bella Cueto","doi":"10.1016/j.endien.2025.101530","DOIUrl":"10.1016/j.endien.2025.101530","url":null,"abstract":"<div><h3>Introduction</h3><div>The tall cell subtype of papillary thyroid carcinoma (PTC) is considered to have poor prognosis, but its diagnostic criteria have been modified on several occasions. The aim of our study was to find the best diagnostic criteria to relate the tall cell subtype with aggressiveness and poor prognosis.</div></div><div><h3>Material and methods</h3><div>In 171 cases of classic subtype and tall cell subtype of PTC, the percentage of cells between two and three times taller than wide (C2−3) and cells more than three times taller than wide (Cx3) was determined by two observers, after obtaining reference images. Groups were made based on the percentage of cells of each component (<2%, between 2 and 10%, between 11 and 30%, between 31 and 50% and >50%) and were correlated with clinical and histopathological data. Interobserver agreement was also assessed.</div></div><div><h3>Results</h3><div>According to the current WHO classification criteria, only 8 cases (5%) of tall cell subtype were identified. The comparison of the risk of recurrence at 5 years based on the percentage and type of cells showed that it increased significantly from >10% of the Cx3 cell component, while there were no significant differences in recurrence rate with any C2−3 cell percentages. Very good interobserver agreement was obtained (Kappa index: 0.83).</div></div><div><h3>Conclusions</h3><div>We consider relevant reporting the presence of Cx3 cells from 10% in PTC as it is associated with a significant increase in the recurrence rate at 5 years. Interobserver agreement is very good if reference images are available.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101530"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.endien.2025.101524
Luis Francisco de Miguel Rodríguez , Julieta Romina Arbat , Katherine García Malpartida , Pablo Fernández Collazo , Carlos Morillas Ariño
{"title":"Solitary fibrous tumor in the thyroid gland as an incidental finding","authors":"Luis Francisco de Miguel Rodríguez , Julieta Romina Arbat , Katherine García Malpartida , Pablo Fernández Collazo , Carlos Morillas Ariño","doi":"10.1016/j.endien.2025.101524","DOIUrl":"10.1016/j.endien.2025.101524","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101524"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atypical development of hypopituitarism due to septic embolism: A case report","authors":"Jordi Tortosa-Carreres , Lorena Hernández-Rienda , Susana Tenés-Rodrigo , Amparo Alba-Redondo , María Luisa Martínez-Triguero","doi":"10.1016/j.endien.2025.101529","DOIUrl":"10.1016/j.endien.2025.101529","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101529"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.endien.2025.101538
Miguel A. Rubio-Herrera , Irene Bretón Lesmes
{"title":"Controversies on the effects of GLP-1 receptor agonist treatment on gastric emptying","authors":"Miguel A. Rubio-Herrera , Irene Bretón Lesmes","doi":"10.1016/j.endien.2025.101538","DOIUrl":"10.1016/j.endien.2025.101538","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 2","pages":"Article 101538"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.endien.2025.101523
Juan Pedro-Botet , Francisco Arrieta , Manuel Botana , José A. Gimeno-Orna , José I. Martínez-Montoro , Emilio Ortega-Martínez de Victoria , Josep Ribalta , Víctor Sánchez-Margalet , Antonio Pérez-Pérez , on behalf of the Grupo de Trabajo de Enfermedad Cardiovascular de la Sociedad Española de Diabetes
Patients with type 2 diabetes mellitus (T2DM) managed in both hospital and out-ofhospital settings usually have a high/very high cardiovascular risk, with a high burden of cardiovascular disease. All this justifies that the reduction of low-density lipoprotein cholesterol is the main therapeutic goal in T2DM. However, residual cardiovascular risk is very prevalent in T2DM, and is usually associated with atherogenic dyslipidemia and hyperlipoproteinemia(a); therefore, it is also necessary to reverse these lipoprotein abnormalities to achieve effective cardiovascular prevention. Given the considerable armamentarium of lipid-lowering drugs currently available, the Cardiovascular Disease Working Group of the Spanish Diabetes Society has considered it appropriate to carry out a narrative review and update of the effectiveness of these lipid-lowering drugs in the population with T2DM taking into account their effect on the lipoprotein profile and their potential impact on glycemic control.
{"title":"Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society","authors":"Juan Pedro-Botet , Francisco Arrieta , Manuel Botana , José A. Gimeno-Orna , José I. Martínez-Montoro , Emilio Ortega-Martínez de Victoria , Josep Ribalta , Víctor Sánchez-Margalet , Antonio Pérez-Pérez , on behalf of the Grupo de Trabajo de Enfermedad Cardiovascular de la Sociedad Española de Diabetes","doi":"10.1016/j.endien.2025.101523","DOIUrl":"10.1016/j.endien.2025.101523","url":null,"abstract":"<div><div>Patients with type 2 diabetes mellitus (T2DM) managed in both hospital and out-ofhospital settings usually have a high/very high cardiovascular risk, with a high burden of cardiovascular disease. All this justifies that the reduction of low-density lipoprotein cholesterol is the main therapeutic goal in T2DM. However, residual cardiovascular risk is very prevalent in T2DM, and is usually associated with atherogenic dyslipidemia and hyperlipoproteinemia(a); therefore, it is also necessary to reverse these lipoprotein abnormalities to achieve effective cardiovascular prevention. Given the considerable armamentarium of lipid-lowering drugs currently available, the Cardiovascular Disease Working Group of the Spanish Diabetes Society has considered it appropriate to carry out a narrative review and update of the effectiveness of these lipid-lowering drugs in the population with T2DM taking into account their effect on the lipoprotein profile and their potential impact on glycemic control.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 2","pages":"Article 101523"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.endien.2025.101521
Alessandro Gentilin , Antonio Cevese
{"title":"PPGAI index as a photoplethysmographic biomarker for type 2 diabetes mellitus","authors":"Alessandro Gentilin , Antonio Cevese","doi":"10.1016/j.endien.2025.101521","DOIUrl":"10.1016/j.endien.2025.101521","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 2","pages":"Article 101521"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号